arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PRECIGEN, INC.

PGEN
$7.22 ▲ +0.32 (+4.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
57 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECIGEN, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6B
Dividend Yield
Revenue Growth None
Op. Margin -25.8%
ROIC -5.3%
FCF / Share $-0.12
Trailing P/E
Price / Book 127.0x
FCF Yield
Debt / Equity 4.62
info Valuation on last close. End-of-day price, Aug 7, 2026.

57-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$23.25M
↑ +1215.9%
Net Income Profit after all expenses
$-7.93M
↑ +85.4%
Operating Margin Operating profit as % of sales
-25.8%
↑ +87.8%
FCF / Share Free cash flow per share
$-0.12
↓ -115.8%
Long-Term Debt Long-term obligations
$93.52M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health
13
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 57 quarters